• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新旧标准之争:不断演变的复发缓解型多发性硬化症诊断标准的影响。

New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.

机构信息

Department of Neurology, St. Vincent's University Hospital, Dublin, Ireland/School of Medicine & Medical Science, University College Dublin, Dublin, Ireland.

出版信息

Mult Scler. 2019 May;25(6):867-870. doi: 10.1177/1352458518770088. Epub 2018 Apr 12.

DOI:10.1177/1352458518770088
PMID:29648501
Abstract

The International Panel on Diagnosis of Multiple Sclerosis (MS) recently revised the 2010 McDonald criteria and made recommendations for revision, allowing for the earliest possible, accurate diagnosis of MS. For relapsing-remitting MS, positive, unmatched cerebrospinal fluid oligoclonal bands may substitute for dissemination in time. Symptomatic lesions, including brainstem and spinal cord, may demonstrate dissemination in space or in time if enhancing (with the exception of the optic nerve). Cortical and juxtacortical lesions are equivalent. In this retrospective analysis, we applied revised criteria to 250 patients previously diagnosed with relapsing-remitting MS according to 2010 criteria and assessed for change in diagnostic times. There was a significant improvement in time to diagnosis between 2010 and 2017 groups ( p < 0.01). Median time to diagnosis according to McDonald 2010 was 7.4 months, compared with 2.3 months for McDonald 2017. Use of cerebrospinal fluid results most frequently resulted in a reduction in time to diagnosis. Symptomatic gadolinium-enhancing lesions led to earliest diagnostic times.

摘要

国际多发性硬化症诊断小组(MS)最近修订了 2010 年麦当劳标准,并提出了修订建议,以便尽早、准确地诊断多发性硬化症。对于复发缓解型多发性硬化症,阳性、不匹配的脑脊液寡克隆带可替代时间上的传播。如果增强(视神经除外),包括脑干和脊髓在内的症状性病变可能在空间或时间上显示出传播。皮质和皮质下病变是等同的。在这项回顾性分析中,我们根据 2010 年的标准对 250 例以前诊断为复发缓解型多发性硬化症的患者应用了修订后的标准,并评估了诊断时间的变化。与 2010 年组相比,2017 年组的诊断时间有显著改善(p<0.01)。根据麦当劳 2010 年的标准,中位数诊断时间为 7.4 个月,而根据麦当劳 2017 年的标准为 2.3 个月。脑脊液结果的使用最常导致诊断时间的缩短。症状性钆增强病变导致最早的诊断时间。

相似文献

1
New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.新旧标准之争:不断演变的复发缓解型多发性硬化症诊断标准的影响。
Mult Scler. 2019 May;25(6):867-870. doi: 10.1177/1352458518770088. Epub 2018 Apr 12.
2
Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis.2017 年 McDonald 标准在提示复发缓解型多发性硬化的首次脱髓鞘事件患者中的诊断价值。
Eur J Neurol. 2019 Mar;26(3):540-545. doi: 10.1111/ene.13853. Epub 2018 Dec 1.
3
Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis.2017年麦克唐纳标准对复发缓解型多发性硬化症早期诊断的影响
Front Neurol. 2019 Mar 15;10:188. doi: 10.3389/fneur.2019.00188. eCollection 2019.
4
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.采用 2016 年 MAGNIMS 和 2010 年 McDonald 标准预测临床孤立综合征患者的多发性硬化症诊断:一项回顾性研究。
Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.
5
Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002.1988年至2002年东京某大学医院多发性硬化症住院患者的临床及实验室特征
Intern Med. 2005 Jun;44(6):560-6. doi: 10.2169/internalmedicine.44.560.
6
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.多发性硬化症的诊断:2017 年麦当劳标准修订版。
Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
7
Primary progressive multiple sclerosis diagnostic criteria: a reappraisal.原发性进行性多发性硬化症的诊断标准:再评价。
Mult Scler. 2009 Dec;15(12):1459-65. doi: 10.1177/1352458509348422. Epub 2009 Dec 7.
8
Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.临床孤立综合征后 2017 年 McDonald 标准对复发缓解型多发性硬化症的真实世界评估证实了诊断时间的提前。
J Neurol. 2024 Jan;271(1):125-133. doi: 10.1007/s00415-023-11905-w. Epub 2023 Aug 31.
9
Oligoclonal band versus chitinase-3-like protein-1 in CSF of newly diagnosed relapsing remitting multiple sclerosis.新诊断复发缓解型多发性硬化症患者脑脊液中寡克隆带与几丁质酶-3样蛋白-1的比较
Egypt J Immunol. 2023 Jan;30(1):42-48.
10
MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.MRI 和实验室特征及国际标准在儿童和青少年多发性硬化症诊断中的表现:一项前瞻性队列研究。
Lancet Child Adolesc Health. 2018 Mar;2(3):191-204. doi: 10.1016/S2352-4642(18)30026-9. Epub 2018 Feb 1.

引用本文的文献

1
Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria-a nationwide population-based registry study over five decades.不断演变的诊断标准时代多发性硬化症的发病率和患病率——一项基于全国人群登记的五十年研究
Mult Scler J Exp Transl Clin. 2025 Mar 16;11(1):20552173251326173. doi: 10.1177/20552173251326173. eCollection 2025 Jan-Mar.
2
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.多发性硬化症中B细胞活化的脑脊液生物标志物:临床视角
J Neurol. 2025 Feb 17;272(3):211. doi: 10.1007/s00415-025-12907-6.
3
Building digital patient pathways for the management and treatment of multiple sclerosis.
构建用于多发性硬化症管理和治疗的数字患者路径。
Front Immunol. 2024 Feb 15;15:1356436. doi: 10.3389/fimmu.2024.1356436. eCollection 2024.
4
The diagnosis of multiple sclerosis: what has changed in diagnostic criteria?多发性硬化症的诊断:诊断标准有哪些变化?
Pol J Radiol. 2023 Dec 12;88:e574-e581. doi: 10.5114/pjr.2023.133677. eCollection 2023.
5
From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology.从识别到治疗:神经退行性疾病病理学中生物标志物的意义。
Int J Mol Sci. 2023 Nov 9;24(22):16119. doi: 10.3390/ijms242216119.
6
Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.全球多发性硬化症诊断障碍:多发性硬化症国际联合会 MS 图谱,第三版的数据。
Neurology. 2023 Aug 8;101(6):e624-e635. doi: 10.1212/WNL.0000000000207481. Epub 2023 Jun 15.
7
[Performance of the revised 2017 McDonald criteria].[2017年修订的麦克唐纳标准的表现]
Nervenarzt. 2023 Jun;94(6):538-545. doi: 10.1007/s00115-022-01410-2. Epub 2022 Dec 1.
8
Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis.神经丝轻链作为多发性硬化症诊断的生物标志物。
EXCLI J. 2021 Aug 16;20:1308-1325. doi: 10.17179/excli2021-3973. eCollection 2021.
9
The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database.基于全国处方数据库的希腊多发性硬化症行政患病率
Front Neurol. 2020 Sep 29;11:1012. doi: 10.3389/fneur.2020.01012. eCollection 2020.
10
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers.多发性硬化症中的认知障碍:脑脊液生物标志物带来的启示
Neural Regen Res. 2021 Jan;16(1):36-42. doi: 10.4103/1673-5374.286949.